Description
About KLOW
KLOW is a defined four-component research blend combining GHK-Cu, BPC-157, TB-500 and KPV in a single lyophilised preparation.
This 80mg format contains 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500 and 10mg KPV, providing a fixed 5:1:1:1 composition by mass.
Each component represents a different but partly overlapping area of experimental biology.
GHK-Cu is a copper-binding tripeptide investigated extensively in fibroblast, collagen and extracellular-matrix research. BPC-157 is a 15-amino-acid peptide studied in models involving fibroblast migration, cellular adhesion and connective-tissue biology. TB-500 is associated with an actin-binding region of thymosin beta-4 and is investigated in relation to cytoskeletal organisation and cell movement.
KPV is a three-amino-acid peptide derived from the C-terminal region of alpha-melanocyte-stimulating hormone and has been investigated in epithelial and immune-cell systems involving inflammatory signalling, including NF-κB and MAPK pathways.
Combining these four materials creates a fixed research format spanning extracellular-matrix production and remodelling, fibroblast behaviour, cellular migration and inflammatory-response biology.
The published evidence for these research areas derives principally from studies of the individual components rather than controlled research demonstrating equivalent or synergistic effects from the complete KLOW blend itself.
Pronoia supplies KLOW in an 80mg multi-component research format with batch traceability and supporting documentation available for the supplied material.
Product Specification
Product: KLOW
GHK-Cu content: 50mg
BPC-157 content: 10mg
TB-500 content: 10mg
KPV content: 10mg
Total content: 80mg
Blend ratio: 5:1:1:1 by mass
Material class: Four-component peptide research blend
Research focus: Extracellular-matrix biology, fibroblast behaviour, cell migration, tissue remodelling and inflammatory signalling
Form: Lyophilised multi-component research preparation
Pronoia minimum purity standard: ≥99%
Batch traceability: Maintained
SKU: PB-KLOW-80
Testing & Batch Documentation
Pronoia maintains a structured quality, testing and traceability process for KLOW, with supporting documentation retained for the supplied research material.
- Batch-tested research material
- Pronoia minimum accepted purity standard of ≥99%
- Defined 50mg / 10mg / 10mg / 10mg blend composition
- Full batch traceability
- Batch-separated and labelled inventory
- Physical inventory routinely reconciled with digital stock records
- Temperature-controlled cold storage
- Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation available
Because KLOW is a multi-component preparation, analytical reporting may differ from that used for a single isolated peptide.
The applicable Certificate of Analysis should therefore be treated as the authoritative reference for the identity, composition, purity and analytical results reported for an individual batch.
Research Context
KLOW combines four distinct research materials whose published biological findings should be considered individually before considering the rationale for investigating them within the same preparation.
There is currently substantially more published evidence for GHK-Cu, BPC-157, TB-500 or thymosin-beta-4-related sequences, and KPV individually than for the exact four-component KLOW formulation.
GHK-Cu — collagen and extracellular-matrix biology
GHK-Cu is a copper-binding tripeptide investigated extensively in fibroblast and extracellular-matrix models.
Published experiments using cultured fibroblasts have reported increased collagen synthesis following GHK-Cu exposure.
Research has also examined regulation of matrix metalloproteinases and their inhibitors. GHK-Cu has been reported to increase MMP-2 expression together with TIMP-1 and TIMP-2 secretion, demonstrating effects on both production and controlled remodelling of extracellular matrix.
These findings make the GHK-Cu component relevant to experimental studies examining:
- Fibroblast activity
- Collagen production
- Extracellular-matrix formation
- Matrix turnover and remodelling
- Connective-tissue-response biology
BPC-157 — fibroblast migration and connective-tissue biology
BPC-157 has been investigated in tendon-derived fibroblast systems examining cellular movement, spreading, survival and adhesion-related signalling.
Under specific experimental conditions, researchers reported:
- Increased tendon-fibroblast migration
- Increased fibroblast spreading
- Increased survival during experimentally induced oxidative stress
- Increased F-actin formation
- Increased activation of FAK and paxillin signalling associated with cellular adhesion and movement
These findings make BPC-157 relevant to research examining fibroblast behaviour and cellular processes involved in connective-tissue-response models.
TB-500 — actin-associated and cytoskeletal research
Published analytical research on material described as TB-500 identified an N-terminally acetylated 17–23 fragment of thymosin beta-4, represented by the sequence Ac-LKKTETQ.
This sequence corresponds to a region associated with thymosin-beta-4 actin-binding biology.
Actin forms a major part of the cellular cytoskeleton — the internal structural framework that enables cells to maintain shape, reorganise and move.
TB-500-related research therefore sits within experimental areas involving:
- Actin-associated cellular organisation
- Cytoskeletal dynamics
- Cell migration and motility
- Structural cell biology
The TB-500 evidence requires careful interpretation. Much of the wider biological literature associated with this region derives from full-length thymosin beta-4 or related sequences rather than the acetylated TB-500 fragment itself.
More recent experimental research has also indicated that some wound-model activity attributed to TB-500 may differ between the parent peptide and its metabolites.
KPV — inflammatory signalling and epithelial biology
KPV is the tripeptide Lys-Pro-Val and corresponds to residues 11–13 of alpha-melanocyte-stimulating hormone.
It has been investigated particularly in epithelial and immune-cell models examining inflammatory signalling.
In cultured human intestinal epithelial cells, researchers reported that KPV reduced activation of two major inflammatory signalling systems:
- NF-κB signalling
- MAP kinase signalling, including ERK, JNK and p38 pathways
KPV exposure was also associated with reduced expression and secretion of pro-inflammatory signalling molecules under the experimental conditions used.
Research identified the peptide transporter PepT1 as one route through which KPV can enter intestinal epithelial and immune cells.
These findings provide an experimental framework for investigating how a short peptide can influence intracellular inflammatory-response pathways.
KPV has also been examined in mouse models of intestinal inflammation.
Across experimental colitis models, researchers reported reductions in inflammatory changes and inflammatory-marker expression following KPV exposure.
Separate research indicated that some of these effects could occur independently of functional melanocortin-1 receptor signalling, illustrating that KPV biology may extend beyond a simple classical melanocortin-receptor mechanism.
These findings make KPV particularly relevant to research involving:
- NF-κB and MAPK signalling
- Pro-inflammatory cytokine regulation
- Intestinal epithelial-cell biology
- Immune-cell signalling
- PepT1-mediated peptide transport
- Barrier and inflammatory-response models
Why study the four components together?
The scientific rationale for a KLOW-type preparation comes from the different but overlapping biological territories represented by its components:
- GHK-Cu contributes copper-peptide, collagen and extracellular-matrix research
- BPC-157 contributes fibroblast migration, adhesion and connective-tissue-response research
- TB-500 contributes actin-associated, cytoskeletal and cell-migration research
- KPV contributes epithelial, immune-cell and inflammatory-signalling research
A fixed preparation allows all four materials to be present within the same experimental system at a defined composition, making KLOW relevant to studies examining multiple cellular, matrix-remodelling and inflammatory pathways in parallel.
This should not be interpreted as evidence that the four components act synergistically or that biological findings reported for each material individually have been demonstrated for the complete KLOW blend.
The available evidence remains primarily laboratory and preclinical. It does not establish clinical efficacy, safety or suitability for human or veterinary use.
Storage & Handling
KLOW is supplied in lyophilised form and should be stored according to the conditions specified by Pronoia and the applicable batch documentation.
Pronoia stock is maintained in temperature-controlled cold storage and organised by identifiable batch prior to dispatch.
The material should be protected from unnecessary exposure to heat, moisture and light and handled using appropriate laboratory procedures.
Because KLOW is a multi-component preparation containing GHK-Cu, some variation in colour or physical appearance may occur between supplied batches. Batch documentation and analytical results should be used when assessing product specification rather than appearance alone.
Where batch-specific storage or handling information is supplied, that information should take precedence.
UK Delivery
KLOW is dispatched from Pronoia’s UK stock using tracked delivery.
Current availability and dispatch information are shown directly on the product page, with tracking supplied following dispatch.
Orders are prepared through Pronoia’s established research-product fulfilment process, with applicable delivery conditions remaining subject to Pronoia’s current delivery terms.
Research Use
KLOW supplied by Pronoia Bio is intended for laboratory research and experimental use only.
It is not supplied for human or veterinary use and should not be treated as a medicine or consumer healthcare product.
Pronoia does not provide dosage, treatment or administration guidance for this research material.
